BIT:PRL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. More Details


Snowflake Analysis

Outstanding track record with high growth potential.

Share Price & News

How has Pierrel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRL is more volatile than 90% of Italian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PRL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Italian stocks.


Market Performance


7 Day Return

-3.0%

PRL

-0.5%

IT Pharmaceuticals

1.3%

IT Market


1 Year Return

51.2%

PRL

-3.8%

IT Pharmaceuticals

6.6%

IT Market

Return vs Industry: PRL exceeded the Italian Pharmaceuticals industry which returned -3.8% over the past year.

Return vs Market: PRL exceeded the Italian Market which returned 6.7% over the past year.


Shareholder returns

PRLIndustryMarket
7 Day-3.0%-0.5%1.3%
30 Day30.6%-4.6%0.7%
90 Day23.2%-4.3%4.7%
1 Year51.2%51.2%-0.7%-3.8%9.8%6.6%
3 Year20.4%10.2%28.2%13.7%4.1%-6.0%
5 Year-36.1%-41.5%33.2%11.6%10.0%-12.9%

Long-Term Price Volatility Vs. Market

How volatile is Pierrel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pierrel undervalued compared to its fair value and its price relative to the market?

1.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRL (€0.23) is trading below our estimate of fair value (€0.23)

Significantly Below Fair Value: PRL is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PRL is good value based on its PE Ratio (17.4x) compared to the XE Pharmaceuticals industry average (23.7x).

PE vs Market: PRL is good value based on its PE Ratio (17.4x) compared to the Italian market (21x).


Price to Earnings Growth Ratio

PEG Ratio: PRL is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: PRL is overvalued based on its PB Ratio (3.6x) compared to the XE Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Pierrel forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

39.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRL's forecast earnings growth (39.3% per year) is above the savings rate (1.9%).

Earnings vs Market: PRL's earnings (39.3% per year) are forecast to grow faster than the Italian market (22% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PRL's revenue (27% per year) is forecast to grow faster than the Italian market (4.7% per year).

High Growth Revenue: PRL's revenue (27% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PRL's Return on Equity is forecast to be low in 3 years time (20%).


Next Steps

Past Performance

How has Pierrel performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRL has high quality earnings.

Growing Profit Margin: PRL's current net profit margins (15%) are higher than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: PRL has become profitable over the past 5 years, growing earnings by 24.6% per year.

Accelerating Growth: PRL's earnings growth over the past year (242.5%) exceeds its 5-year average (24.6% per year).

Earnings vs Industry: PRL earnings growth over the past year (242.5%) exceeded the Pharmaceuticals industry 11.2%.


Return on Equity

High ROE: PRL's Return on Equity (20.8%) is considered high.


Next Steps

Financial Health

How is Pierrel's financial position?


Financial Position Analysis

Short Term Liabilities: PRL's short term assets (€10.2M) exceed its short term liabilities (€8.4M).

Long Term Liabilities: PRL's short term assets (€10.2M) do not cover its long term liabilities (€10.4M).


Debt to Equity History and Analysis

Debt Level: PRL's debt to equity ratio (78.7%) is considered high.

Reducing Debt: PRL's debt to equity ratio has reduced from 699.5% to 78.7% over the past 5 years.

Debt Coverage: PRL's debt is well covered by operating cash flow (36.8%).

Interest Coverage: PRL earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Pierrel current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRL's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

€527k

CEO Compensation


CEO

Fulvio Citaredo (58 yo)

no data

Tenure

€527,251

Compensation

Dr. Fulvio Citaredo serves as the Chief Executive Officer and Director of Pierrel S.p.A. since 2020 and serves as General Manager since October 2020. Dr. Citaredo served as its Corporate General Manager of...


CEO Compensation Analysis

Compensation vs Market: Fulvio's total compensation ($USD628.13K) is above average for companies of similar size in the Italian market ($USD372.98K).

Compensation vs Earnings: Fulvio's compensation has increased by more than 20% in the past year.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pierrel S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pierrel S.p.A.
  • Ticker: PRL
  • Exchange: BIT
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €51.727m
  • Shares outstanding: 228.88m
  • Website: https://www.pierrelgroup.com

Location

  • Pierrel S.p.A.
  • s.s. Appia 7 bis 46/48
  • Capua
  • Caserta
  • 81043
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRLBIT (Borsa Italiana)YesCommon StockITEURMay 2006
2FJDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2006
PRLMBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURMay 2006

Biography

Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. The company is involved in the development of various types of drugs, such a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/07 18:31
End of Day Share Price2021/03/05 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.